No to EMA’s provision of confidential scientific advice to drug companies (November 2017)

Paris, 28 November 2017 Prescrire, along with around 20 civil society organisations, has signed a joint declaration drawing attention to potential problems posed by the provision of confidential scientific advice by the European Medicines Agency to pharmaceutical companies, especially a decline in regulatory standards, a risk of institutional capture, and a total lack of transparency surrounding the activity of European regulatory authorities.

Read more...

Proposed changes to EMA’s access to documents policy fall short on proactive disclosure (May 2017)

Brussels, 18 May 2017 In a joint response to the EMA's consultation on its policy on access to documents, Health Action International, the International Society of Drug Bulletins, NoGracias, the Nordic Cochrane Centre and Prescrire called for a comprehensive public register of all the documents the EMA produces and receives. The coalition also strongly encourages the EMA to increase resources so it can more efficiently handle access requests to documents.

Read more...